There has been a trend of Finnish SPARK alumni to be highly successful in raising new funding for advancing their cases. Two of the latest successes were witnessed when StemSight and Sartar Therapeutics announced remarkable funding decisions.

StemSight announced today that they have raised 500.000 euro seed-round from Voima Ventures and Avohoidon Tutkimussäätiö. Funding goes to further development of StemSight’s cell therapy product for limbal stem cell deficiency.

On last week Sartar Therapeutics announced that they have received 1 million euro non-dilutive R&D loan from Business Finland. That allows the company to advance development of product SAR001 towards clinical trials for the treatment of soft tissue sarcomas.

On behalf of SPARK community we congratulate both of these great teams, and also financiers, for remarkable funding decisions.

Stay tuned for other great news from SPARK Finland community.